BioCentury
ARTICLE | Clinical News

AV4025: Phase Ib data

January 5, 2015 8:00 AM UTC

A double-blind, placebo-controlled, Russian Phase Ib trial in 15 treatment-naïve patients with HCV genotype 1b infection showed that once-daily 20 and 40 mg doses of oral AV-4025 for 3 days were well ...